Year: 2021

WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, which will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients...

Pays off Remaining $25 Million Term Loan NEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) — Aterian, Inc. (Nasdaq: ATER) (“Aterian”) announced today that it has signed an asset backed credit facility with MidCap Financial Trust (“MidCap”), which is managed by a subsidiary of Apollo Global Management, Inc. The credit facility has a three year term and gives Aterian access to up to $50 million in total credit, consisting of $40 million in commitments with an accordion facility of an additional $10 million. On the closing, Aterian has repaid in cash and satisfied all outstanding obligations under its existing $25.0 million term loan with High Trail. Aterian’s Chief Executive Officer, Yaniv Sarig, commented, “This credit facility is a testament to MidCap’s understanding of our business, strong expertise in E-Commerce and their commitment to...

HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The analysis is based on 89 patients enrolled in two Phase II studies in the U.S. (the “U.S. study”) and in Europe and Israel (collectively, the “EU study” and together with the U.S. study, the “Studies”). The primary efficacy endpoint was the number of ventilator free days (VFD) from day 1 through day 28 of the Studies. VFD at day 60 and all-cause mortality at days 28 and 60 were part of the secondary efficacy endpoints in the Studies. The...

MAINZ, Germany, December 27, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET. A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.de/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference. About BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid...

MONACO, Dec. 27, 2021 (GLOBE NEWSWIRE) — Eneti Inc. (NYSE:NETI) (the “Company”) announced today that Seajacks UK Limited, a wholly-owned subsidiary of the Company and a leading provider of installation and maintenance vessels to the offshore wind sector, has signed a contract with Dutch marine contractor, Van Oord. Van Oord has selected the Seajacks Scylla, the largest and most capable vessel in the Seajacks fleet. Currently employed through 2022 in Taiwan, the vessel will move to Europe upon completion of its existing turbine installation contract with Ørsted on the Greater Changhua Offshore Wind Farm. The firm charter duration of the Van Oord contract will generate approximately $60 million of revenue in 2023. Emanuele Lauro, CEO of Eneti, says: “Securing this charter will bring the Scylla back from the Asia Pacific to the European...

To NASDAQ Copenhagen A/S   Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 27 December 2021  Company announcement number 107/2021 Fixing of coupon rate effective from 1 January 2022With effect from 1 January 2022, the coupon rate of the following bonds financing RD Euribor3®, RD Stibor3®, RD Stibor3® Green, RD Nibor3®, RD Cibor6®, RD Cibor6® Green and FlexKort® will be adjusted.          Please find the data in the attached file.     The Executive Board Any additional questions should be addressed to Chief Analyst Hella Gebhardt Rønnebæk, Phone +45 45 13 20 68.    AttachmentsNr. 107_Fastsaettelse af kuponrente pr. 01.01.2022_ukBilag til selskabsmeddelelse nr. 107-2021_uk

Parkersburg, WV, Dec. 27, 2021 (GLOBE NEWSWIRE) —  Kronos Advanced Technologies, Inc., (OTC: KNOS), revenue-generating product development and production company that has significantly changed the way air is moved, filtered, and sterilized, is pleased to announce a successful contract to procure Personal Protective Equipment (“PPE”), medical gloves, medical and health masks as well as COVID-19 Test Kit Products. Kronos has initiated national marketing efforts to provide PPE supplies and Covid test kits with direct product sales from PPE manufacturers to clients and governments. This is a significant contract as Kronos continues to execute on its growth strategy. The Company is working towards adding additional supply contracts in 2022. Michael Rubinov, CEO of Kronos, stated, “We are pleased to announce the supplies...

Havila Shipping ASA has entered into a contract with Harbour Energy for the PSV vessel Havila Commander.The contract is for a firm period of four wells, with one well option. Estimated commencement is January 2022. Contacts: CEO Njål Sævik, +47 909 35 722CFO Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Helsinki, 27 December 2021 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) announces the following publication dates of the Group’s financial reports in 2022, as well as the Annual General Meeting:Date Publication15.03.2022 Multitude SE: 2021 preliminary results31.03.2022 Multitude SE: full year 2021 results31.03.2022 Ferratum Capital Germany GmbH: full year 2021 results31.03.2022 Ferratum Bank p.l.c.: full year 2021 results27.04.2022 Multitude SE: Annual General Meeting12.05.2022 Multitude SE: Q1 2022 results18.08.2022 Multitude SE: H1 2022 results18.08.2022 Ferratum Capital Germany GmbH: H1 2022 results18.08.2022 Ferratum...